Understanding CPS1 Deficiency
At a Glance
CPS1 deficiency is a rare inherited urea cycle disorder that prevents the body from safely clearing ammonia. Severe cases appear within days of birth, while partial enzyme activity may cause later crises after illness, fasting, high-protein meals, or surgery.
Learning that your child has Carbamoyl Phosphate Synthetase 1 (CPS1) deficiency can be overwhelming. This condition is a rare urea cycle disorder (UCD). Its exact prevalence varies by population, but some reports estimate it affects approximately 1 in 150,000 to 200,000 newborns [1][2]. It is a life-long metabolic condition that requires careful management, but understanding the biology behind it is the first step in advocating for your child’s care.
The Role of the CPS1 Enzyme
To understand this condition, it helps to think of the body as a factory that must constantly dispose of waste. When we eat protein, the normal breakdown process produces ammonia, a substance that is highly toxic, especially to the brain [3].
In a healthy body, the urea cycle—a series of five primary chemical reactions in the liver—converts ammonia into urea, which is then safely removed through urine. CPS1 is the enzyme responsible for the very first step of this cycle [4]. It lives inside the mitochondria (the energy-producing centers of cells) and works like a gatekeeper.
When the CPS1 enzyme is missing or not working correctly:
- Ammonia builds up: Because the “gate” is closed, ammonia cannot enter the urea cycle and begins to accumulate in the blood (hyperammonemia) [5].
- Citrulline levels drop: Citrulline is a compound created later in the urea cycle. Because the first step is blocked, the body cannot produce enough citrulline [6][7].
- Activation fails: The CPS1 enzyme normally requires a “starter” molecule called N-acetylglutamate (NAG) to turn on. In some cases, the enzyme is present but cannot respond to this starter signal [6][8].
How CPS1 Deficiency is Inherited
CPS1 deficiency is an autosomal recessive disorder [1]. This means it is a genetic condition that a child inherits from both parents.
- Carriers: Usually, both parents are “carriers.” This means they each have one working copy of the CPS1 gene and one non-working copy. Carriers typically have no symptoms because one working gene is enough to keep the urea cycle functioning normally [4].
- The 25% Rule: When two carriers have a child, there is a:
- 25% chance the child will inherit two non-working genes and have CPS1 deficiency.
- 50% chance the child will inherit one working gene and one non-working gene, making them a carrier like their parents.
- 25% chance the child will inherit two working genes and be neither affected nor a carrier [9].
This inheritance happens purely by chance and is not caused by anything a parent did before or during pregnancy.
Two Ways the Condition Presents
Doctors generally categorize CPS1 deficiency into two types based on when symptoms first appear. The timing often depends on how much “residual” (remaining) enzyme activity the child has [5].
Neonatal-Onset (Severe)
This is the most common and severe form, usually appearing within the first few days of life [10].
- The “Window”: Most newborns with CPS1 deficiency appear perfectly healthy at birth. However, once they begin digesting protein, ammonia begins to rise rapidly [1][11].
- Rapid Progression: Within 24 to 72 hours, the child may become very sleepy, stop feeding well, or have trouble breathing. Without immediate treatment to lower ammonia, this can quickly lead to a coma or permanent neurological injury [12][11].
Late-Onset (Partial)
In late-onset CPS1 deficiency, the enzyme has some limited ability to function. Symptoms may not appear until months or even years after birth [13].
- Triggers: A crisis is often “triggered” by something that puts stress on the body, such as a high-protein meal, a common viral infection (like the flu), fasting, or surgery [12][14].
- Varied Symptoms: Presentation can be subtle or confusing. A child might experience episodes of vomiting, coordination problems (ataxia), or sudden behavioral changes or acute confusion [9][15].
For information on recognizing these emergencies, see the symptoms and emergency care pages. Any confirmed high elevation requires specialized care from a metabolic team [16].
Common questions in this guide
What is CPS1 deficiency?
How does a child inherit CPS1 deficiency?
What are the first signs of severe CPS1 deficiency in a newborn?
What can trigger a late-onset CPS1 deficiency crisis?
Is CPS1 deficiency always diagnosed in the newborn period?
What does a high ammonia level mean for a child with CPS1 deficiency?
Can other family members be tested for CPS1 deficiency?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Has genetic testing confirmed that my child has two pathogenic variants in the CPS1 gene?
- 2.Does my child have 'neonatal-onset' or 'late-onset' CPS1 deficiency, and how does that affect their long-term outlook?
- 3.What was the highest ammonia level my child reached during their first crisis, and what does that mean for their brain health?
- 4.Can we perform carrier testing for our other children or relatives?
- 5.Are there specific metabolic specialists you recommend we consult with for ongoing care?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
A successful liver transplantation in a patient with neonatal-onset carbamoyl phosphate synthetase-1 deficiency.
Arslan S, Kocaoğlu İ, Yaralı O, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2024; (37(10)):924-929 doi:10.1515/jpem-2024-0240.
PMID: 39158197 - 2
Long-term follow-up of children with carbamoyl phosphate synthase 1 deficiency detected in newborn screening.
Zhang Z, Tong F, Chen C, et al.
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2023; (52(6)):721-726 doi:10.3724/zdxbyxb-2023-0359.
PMID: 37986659 - 3
From consanguinity to crisis: a rare cause of neonatal encephalopathy.
Kar S, Mude P, Som TK, Sahoo T
BMJ case reports 2026; (19(2)) doi:10.1136/bcr-2025-267688.
PMID: 41667206 - 4
Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy.
Khoja S, Nitzahn M, Hermann K, et al.
Molecular genetics and metabolism 2018; (124(4)):243-253 doi:10.1016/j.ymgme.2018.04.001.
PMID: 29801986 - 5
A hypomorphic model of CPS1 deficiency for investigating the effects of hyperammonemia on the developing nervous system.
Bakshi S, Diep T, Willis BJ, et al.
Disease models & mechanisms 2025; (18(7)) doi:10.1242/dmm.052303.
PMID: 40421838 - 6
Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis.
de Cima S, Polo LM, Díez-Fernández C, et al.
Scientific reports 2015; (5()):16950 doi:10.1038/srep16950.
PMID: 26592762 - 7
Carbamoylphosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients.
Ali EZ, Khalid MK, Yunus ZM, et al.
European journal of pediatrics 2016; (175(3)):339-46 doi:10.1007/s00431-015-2644-z.
PMID: 26440671 - 8
Therapeutic effect of N-carbamylglutamate in CPS1 deficiency.
Sugiyama Y, Shimura M, Ogawa-Tominaga M, et al.
Molecular genetics and metabolism reports 2020; (24()):100622 doi:10.1016/j.ymgmr.2020.100622.
PMID: 32670798 - 9
Clinical features and CPS1 variants in Chinese patients with carbamoyl phosphate synthetase 1 deficiency.
Dong H, Sang T, Ma X, et al.
BMC pediatrics 2024; (24(1)):539 doi:10.1186/s12887-024-05005-5.
PMID: 39174957 - 10
Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency.
Choi Y, Oh A, Lee Y, et al.
Clinica chimica acta; international journal of clinical chemistry 2022; (526()):55-61 doi:10.1016/j.cca.2021.11.029.
PMID: 34973183 - 11
Neonatal carbamoyl phosphate synthetase I deficiency with severe hyperammonemic coma: the first report from Palestine.
Assi AK, Odeh A, Awwad HH, et al.
BMC pediatrics 2026; (26(1)).
PMID: 41917863 - 12
Novel compound heterozygote variants: c.4193_4206delinsG (p.Leu1398Argfs*25), c.793C > A (p.Pro265Thr), in the CPS1 gene (NM_001875.4) causing late onset carbamoyl phosphate synthetase 1 deficiency-Lessons learned.
Lin HT, Enchautegui-Colon Y, Huang YR, et al.
Molecular genetics and metabolism reports 2022; (33()):100942 doi:10.1016/j.ymgmr.2022.100942.
PMID: 36466970 - 13
The current social status in adult patients with urea cycle disorders in Japan.
Kido J, Häberle J, Sugawara K, et al.
Molecular genetics and metabolism 2025; (145(4)):109185 doi:10.1016/j.ymgme.2025.109185.
PMID: 40618446 - 14
N-carbamoylglutamate-responsive carbamoyl phosphate synthetase 1 (CPS1) deficiency: A patient with a novel CPS1 mutation and an experimental study on the mutation's effects.
Yap S, Gougeard N, Hart AR, et al.
JIMD reports 2019; (48(1)):36-44 doi:10.1002/jmd2.12034.
PMID: 31392111 - 15
Carbamoyl phosphate synthetase 1 deficiency manifested in an adult treated with prednisone for polymyositis, and cured by live-donor liver transplantation.
Yokota K, Ohtake A, Yamazaki T, et al.
Molecular genetics and metabolism reports 2025; (43()):101200 doi:10.1016/j.ymgmr.2025.101200.
PMID: 40125546 - 16
Citrulline in the management of patients with urea cycle disorders.
Imbard A, Bouchereau J, Arnoux JB, et al.
Orphanet journal of rare diseases 2023; (18(1)):207 doi:10.1186/s13023-023-02800-8.
PMID: 37480106
This page is for informational purposes only and does not constitute medical advice. A metabolic specialist and your child's healthcare team should guide urgent evaluation, ammonia testing, and individualized care.
Get notified when new evidence is published on Carbamoyl-phosphate synthetase 1 deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.